A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole ...
A ketone body, a molecule derived from the metabolism of acids to obtain energy when glucose is not available, could become ...
Merus NV gained accelerated U.S. FDA approval of Bizengri (zenocutuzumab) as the first and only targeted therapy indicated for NRG1-positive pancreatic adenocarcinoma and non-small-cell lung cancer ...
Methods that may work well for recruiting and retaining white patients for clinical trials may need to be adjusted to ...
Spur Therapeutics Ltd. has selected SPR-301 as lead development candidate from its gene therapy program for a genetically ...
In breast cancer, neoadjuvant chemotherapy reduces the tumor before surgery. However, the response to this treatment does not ...
Beacon Biosignals Inc. can rest easy now that it has received U.S. FDA authorization of its predetermined change control plan ...
Novartis AG lost its bid, at least for now, to delay generic competition to its blockbuster heart drug, Entresto (sacubitril, valsartan), on the basis of patent infringement.
Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.
Eli Lilly and Co.’s weight-loss drug Zepbound (tirzepatide) made headlines yet again as the Indianapolis-based firm disclosed top-line data from the Surmount-5 phase IIIb study. The open-label, ...
Elevar Therapeutics Inc. will license Relay Therapeutics Inc.’s “NDA-ready” bile duct cancer therapy, lirafugratinib (RLY-4008), through a potential $500 million deal as Elevar, an HLB Co. Ltd.
Eterna Therapeutics Inc. has announced plans to evaluate the ability of ERNA-101 to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research ...